Analyst rates Arteris a Buy with a $23 FY 2027 target and 14% upside; chiplet designs are expected to grow from 10% to 30%-35% of projects.
Arteris (NASDAQ:AIP) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive financial data and
Why Arteris Is Back On Investor Radars Arteris (AIP) is drawing fresh attention after expanding its third party IP security assurance program with BAE Systems and SiFive, supported by an additional US$3.3 million from a US defense microelectronics initiative. Arteris has had a choppy stretch, with the share price falling 3.03% over the last day and down 35.20% over 90 days, even as the 30 day share price return of 9.50% and year to date share price gain of 50.19% point to renewed momentum...
Arteris (AIP) has an average rating of buy and mean price target of $39.33, according to analysts po
Earlier this year, Arteris, Inc. expanded its multi-die portfolio with the FlexGen Multi-Die product, designed to help semiconductor companies move from monolithic system-on-chip designs to chiplet-based architectures for AI, high-performance computing, and consumer electronics. The launch aims to tackle one of the hardest problems in multi-die systems, efficient, secure data movement across multiple chips, while giving engineering teams more automation and architectural flexibility as...
Detailed price information for Arteris Inc (AIP-Q) from The Globe and Mail including charting and trades.
Arteris boasts a robust 85% TTM gross margin, yet Q2 saw a 14.1% GAAP net loss, widening 54% QoQ despite revenue growth. Learn more about AIP stock here.
AIP’s NoC/SoC IP benefits from AI chip complexity, offering capital-light royalty tails—but valuation and macro risks suggest a Hold.
This is the newest page. Registered accounts read further back.